X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8677) 8677
Book Chapter (49) 49
Dissertation (25) 25
Conference Proceeding (8) 8
Publication (4) 4
Magazine Article (1) 1
Newspaper Article (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sorafenib (8208) 8208
humans (4806) 4806
oncology (3661) 3661
hepatocellular carcinoma (2932) 2932
cancer (2466) 2466
male (2417) 2417
female (2236) 2236
niacinamide - analogs & derivatives (2147) 2147
middle aged (1893) 1893
aged (1673) 1673
antineoplastic agents - therapeutic use (1482) 1482
sunitinib (1472) 1472
liver cancer (1417) 1417
survival (1348) 1348
treatment outcome (1310) 1310
liver neoplasms - drug therapy (1232) 1232
adult (1191) 1191
carcinoma, hepatocellular - drug therapy (1185) 1185
animals (1076) 1076
care and treatment (1076) 1076
liver neoplasms - pathology (1044) 1044
metastasis (1034) 1034
chemotherapy (1002) 1002
therapy (989) 989
carcinoma, hepatocellular - pathology (973) 973
hepatoma (973) 973
apoptosis (898) 898
prognosis (897) 897
pharmacology & pharmacy (860) 860
carcinoma, renal cell - drug therapy (852) 852
phenylurea compounds (843) 843
tumors (843) 843
gastroenterology & hepatology (842) 842
efficacy (829) 829
kidney neoplasms - drug therapy (821) 821
angiogenesis (811) 811
cell line, tumor (807) 807
antineoplastic agents (803) 803
expression (793) 793
antimitotic agents (764) 764
analysis (731) 731
phenylurea compounds - therapeutic use (700) 700
aged, 80 and over (699) 699
protein kinase inhibitors - therapeutic use (694) 694
antineoplastic agents - pharmacology (691) 691
bevacizumab (688) 688
digestive system diseases (687) 687
renal cell carcinoma (683) 683
retrospective studies (660) 660
antineoplastic agents - adverse effects (645) 645
niacinamide - therapeutic use (617) 617
mice (614) 614
double-blind (606) 606
medicine & public health (603) 603
cancer therapies (595) 595
drug therapy (587) 587
interferon-alpha (583) 583
kinases (582) 582
patients (582) 582
carcinoma (573) 573
disease-free survival (573) 573
vascular endothelial growth factor (565) 565
endothelial growth-factor (553) 553
trial (546) 546
medical prognosis (541) 541
neoplasms (539) 539
research (537) 537
management (532) 532
safety (532) 532
phase-ii (527) 527
liver (521) 521
pyridines - therapeutic use (514) 514
transarterial chemoembolization (513) 513
kidney neoplasms - pathology (511) 511
targeted therapy (500) 500
combination (485) 485
antineoplastic agents - administration & dosage (478) 478
antineoplastic combined chemotherapy protocols - therapeutic use (467) 467
carcinoma, renal cell (464) 464
phenylurea compounds - administration & dosage (455) 455
cell proliferation - drug effects (454) 454
clinical trials (454) 454
hepatocellular-carcinoma (454) 454
health aspects (451) 451
carcinoma, hepatocellular - therapy (442) 442
phenylurea compounds - pharmacology (442) 442
liver neoplasms - therapy (439) 439
growth (436) 436
carcinoma, hepatocellular - mortality (433) 433
liver neoplasms - mortality (433) 433
cell biology (432) 432
phase-ii trial (432) 432
niacinamide - administration & dosage (430) 430
benzenesulfonates - therapeutic use (429) 429
tyrosine kinase inhibitor (422) 422
everolimus (413) 413
apoptosis - drug effects (407) 407
neoplasm staging (403) 403
niacinamide - pharmacology (400) 400
liver neoplasms - metabolism (399) 399
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8185) 8185
Korean (178) 178
German (145) 145
French (121) 121
Japanese (109) 109
Chinese (46) 46
Russian (35) 35
Spanish (33) 33
Portuguese (20) 20
Polish (10) 10
Czech (8) 8
Italian (6) 6
Turkish (4) 4
Hungarian (2) 2
Slovak (2) 2
Catalan (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


World journal of gastroenterology : WJG, ISSN 1007-9327, 09/2018, Volume 24, Issue 36, pp. 4152 - 4163
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 0027-8424, 1737, Volume 111, Issue 14, pp. 5319 - 5324
Journal Article
International journal of nanomedicine, ISSN 1178-2013, 2019, Volume 14, pp. 8445 - 8467
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2020, Volume 38, Issue 3, pp. 193 - 202
PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular... 
ONCOLOGY | SORAFENIB
Journal Article
Acta biomaterialia, ISSN 1742-7061, 2018, Volume 72, pp. 248 - 255
Proposed mechanism of miR-375/Sf-LCC NPs for anti-tumor effects and autophagy inhibition in HCC. [Display omitted] Sorafenib is a first-line drug for... 
microRNA | Hepatocellular carcinoma | Nanoparticle | Nanomedicine | Autophagy | Cancer | DRUG | CELLS | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | TUMOR | SORAFENIB | CHLOROQUINE | MULTIKINASE INHIBITOR | CHEMOTHERAPY | DELIVERY | BREAST-CANCER | MIR-375 | Nanoparticles - chemistry | Humans | Coated Materials, Biocompatible - pharmacology | Delayed-Action Preparations - chemistry | MicroRNAs - pharmacokinetics | Sorafenib - chemistry | MicroRNAs - pharmacology | Calcium Carbonate - chemistry | Lipids - chemistry | Carcinoma, Hepatocellular - drug therapy | Lipids - pharmacology | Nanoparticles - therapeutic use | Delayed-Action Preparations - pharmacology | Delayed-Action Preparations - pharmacokinetics | Liver Neoplasms - pathology | Calcium Carbonate - pharmacokinetics | Coated Materials, Biocompatible - pharmacokinetics | Sorafenib - pharmacokinetics | Liver Neoplasms - drug therapy | Coated Materials, Biocompatible - chemistry | Sorafenib - pharmacology | Hep G2 Cells | Xenograft Model Antitumor Assays | Animals | Lipids - pharmacokinetics | Mice, Nude | Carcinoma, Hepatocellular - pathology | Liver Neoplasms - metabolism | Mice | Calcium Carbonate - pharmacology | MicroRNAs - chemistry | Carcinoma, Hepatocellular - metabolism | Antimitotic agents | Nanoparticles | Pharmacy | Analysis | Calcium carbonate | Drugstores | Hepatoma | Antineoplastic agents
Journal Article
Molecules (Basel, Switzerland), ISSN 1420-3049, 2018, Volume 23, Issue 1, p. 24
Both EGFR and VEGFR-2 play a critical role in tumor growth, angiogenesis and metastasis, and targeting EGFR and VEGFR-2 simultaneously represents a promising... 
Thiourea | Quinazoline | Sorafenib | Molecular docking | TK inhibitor | quinazoline | thiourea | molecular docking | sorafenib | BIOCHEMISTRY & MOLECULAR BIOLOGY | GROWTH | BIOLOGICAL-ACTIVITIES | DERIVATIVES | CHEMISTRY, MULTIDISCIPLINARY | Quinazolines - chemical synthesis | Thiourea - therapeutic use | Antineoplastic Agents - chemical synthesis | Humans | Melanoma, Experimental - drug therapy | Antineoplastic Agents - therapeutic use | Thiourea - pharmacology | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Thiourea - chemical synthesis | Drug Design | Antineoplastic Agents - pharmacology | Cell Survival - drug effects | Molecular Docking Simulation - methods | ErbB Receptors - antagonists & inhibitors | Mice, Inbred C57BL | Sorafenib - chemical synthesis | Sorafenib - analogs & derivatives | Sorafenib - pharmacology | Sorafenib - therapeutic use | Xenograft Model Antitumor Assays | Animals | Quinazolines - therapeutic use | Cell Line, Tumor | Protein Binding | Cell Proliferation - drug effects | Quinazolines - pharmacology | Biotechnology | Model testing | Epidermal growth factor receptors | Melanoma | Thioureas | Kinases | Vascular endothelial growth factor receptors | Anticancer properties | Metastases | Analogs | Angiogenesis | Inhibitors | Antitumor agents | Xenografts | In vivo methods and tests | Cancer
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2018, Volume 36, Issue 2, pp. 332 - 339
Journal Article
Cancer letters, ISSN 0304-3835, 07/2018, Volume 425, pp. 101 - 115
Journal Article
BMC cancer, ISSN 1471-2407, 2019, Volume 19, Issue 1, pp. 568 - 11
BackgroundPatients with hepatocellular carcinoma waiting for liver transplantation are commonly treated with locoregional treatments, such as TACE and... 
Liver cancer | Sorafenib | Perfusion CT | Hepatocellular carcinoma | Neoadjuvant | Feasibility | Liver transplantation | TARGETED THERAPY | SURVIVAL | IMPACT | MODIFIED RECIST | ONCOLOGY | RESPONSE EVALUATION CRITERIA | DOUBLE-BLIND | LOCOREGIONAL THERAPY | INCREASED COMPLICATIONS | RECURRENCE | Liver Transplantation | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Male | Response Evaluation Criteria in Solid Tumors | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Liver Neoplasms - physiopathology | Adult | Female | Neoadjuvant Therapy | Sorafenib - administration & dosage | Carcinoma, Hepatocellular - physiopathology | Drug Tolerance | Liver Neoplasms - drug therapy | Sorafenib - adverse effects | Sorafenib - therapeutic use | Pilot Projects | Blood Flow Velocity | Quality of Life | Aged | Usage | Relapse | Analysis | Liver | Clinical trials | Transplantation | Hepatoma | Research | Drug therapy | Cancer | targeted therapy | increased | response evaluation criteria | complications | impact | survival | Oncology | perfusion ct | Kirurgi | recurrence | modified recist | Surgery | Cancer and Oncology | locoregional therapy | double-blind | Cancer och onkologi
Journal Article
BMC cancer, ISSN 1471-2407, 2019, Volume 19, Issue 1, pp. 954 - 10
Journal Article